Pfizer’s Chantix Produced More Heart Concerns, FDA Says

Pfizer Inc.’s anti-smoking drug Chantix produced a higher rate of heart attacks or strokes in patients using the treatment than those who didn’t take the product, according to an analysis of clinical trials.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.